Milestone Pharmaceuticals Inc. (MIST) · Oct 28, 2026 · Delisting
Bid-price deficiency — Below $1.00 for 30 consecutive business days; cure deadline April 21, 2027
Milestone Pharmaceuticals disclosed a Nasdaq listing deficiency, giving it 180 days to restore its share price or pursue transfer and reverse-split options.
Milestone is newly commercializing CARDAMYST for PSVT while advancing etripamil into Phase 3 development for atrial fibrillation with rapid ventricular rate, so the company is trying to convert its first approved product into a broader cardiovascular platform.
The filing adds a capital-markets problem, not an operating shutdown. Nasdaq says the common shares traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180-day cure period ending April 21, 2027. The listing remains intact for now, and compliance requires at least 10 consecutive business days at or above $1.00. 〔0〕
The practical consequence is added pressure during a commercialization buildout. If the price does not recover, Milestone may need to transfer to the Nasdaq Capital Market and could use a reverse stock split to regain compliance; failure to pursue an eligible path could lead to a delisting notice. That does not change CARDAMYST’s approval, launch, or clinical program directly, but it narrows the company’s flexibility while it is funding commercial execution and pipeline development.
Bottom line: This is a new negative complication around the business rather than a setback to the drug itself. The company has time to cure the deficiency, but the filing puts a reverse split or other listing-preservation action onto the strategic agenda.
Nasdaq compliance deadline, April 21, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!